Fact CheckerSign in

NCT05937620Recruiting

Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian Cancer

Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and Indocyanine Green (ICG) in Patients With Epithelial Ovarian Cancer in Early Stages: Pilot Study

Source: ClinicalTrials.gov · Last updated 9 Feb 2026

Brief summary (registry, in English)

Study to evaluate the diagnostic precision of ICG and 99mTc nanocolloid albumin in sentinel lymph node detection in early ovarian epithelial cancer.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
62 (estimated)
First submitted
20 Jun 2023
Start date
1 Sept 2023
Primary completion date
31 Oct 2026
Lead sponsor
Fundacion Clinic per a la Recerca Biomédica
NCT number
NCT05937620

What you commit to

  • Study type: Interventional
  • Planned participants: 62
  • From 1 Sept 2023 to the primary completion date, 31 Oct 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • History of previous vascular surgery (cava vein, aorta, iliac blood vessels) or radiotherapy in pelvic or para-aortic area.
  • Patient not able to undergo surgery.

Other illness

  • Sentinel lymph node biopsy will not be performed if intraoperative histologic study shows a benign ovarian tumor, low malignancy potential tumor or expansive mucinous histology.

Lab values

  • Hypersensitivity to active principle, to sodium iodide or iodine allergy.

Age

  • Patients \<18 years

Other

  • Pregnancy or breastfeeding
  • Epithelial ovarian tumors stage FIGO III or IV.
  • Impossibility to obtain a biopsy from the tumor.
  • Patients with clinic hyperthyroidism, thyroid autonomous adenomas or focal and diffused autonomous alteration of thyroid gland

Who the study is looking for

  • Patients with adnexal mass diagnosed with high suspicion of malignancy that will undergo intraoperative biopsy or patients with already diagnosed epithelial cancer in early stages in a previous surgery and confirmed by pathology with complete staging indicated.
  • Absence of retroperitoneal ganglionary affectation and metastatic disease evaluated by preoperative imaging techniques.
  • Signing of informed consent by the patient or relative in charge.
  • Women with childbearing potential must compromise to use highly effective contraceptive methods (partner vasectomized, sexual abstinence) until the end of the study (last study visit).

Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Laura Burunat
Coordinator of this site? Confirm its status
BarcelonaSpainRecruiting

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.